spacer
home > > winter 2009 > new economic perspectives
PUBLICATIONS


New Economic Perspectives

Central and eastern Europe – Russia and Ukraine in particular – is one of the most dynamically evolving regions in clinical trials. Post-Soviet countries are very attractive to foreign companies conducting clinical trials, for some of the following reasons:

  • High professional standard of personnel and experience in clinical trials
  • Fast recruitment of patients (the majority of them are undertreated and have no medical insurance)
  • Transparent and consistent regulatory requirements
  • Economic efficiency
  • Social effect (due to access to diagnostics and up-to-date treatment)

The clinical trials market in Ukraine – the focus of this article – exemplifies these benefits.

There are currently 2,574 inpatient clinics and 6,842 outpatient clinics assigned to the Ministry of Health of Ukraine; the total number of beds is 404,212; the total number of doctors is 195,555 (1). Also, there are so-called ‘internal’ industry-sponsored clinics and scientific-research clinics that are assigned to the Academy of Medical Sciences of Ukraine, where significant scientific potential is concentrated. The population of Ukraine is 46,465,691: 21,434,680 men and 25,031,011 women.

A CLOSER LOOK AT UKRAINE

According to an analysis of the data of the Medical Statistics Centre of Ukraine, morbidity is constantly increasing, due to improving diagnostics and a worsening ecological and economic situation. In 2008, general morbidity was 83,068,293 cases. The leading categories of diseases according to the ICD-10 (International Statistical Classification of Diseases and Related Health Problems) relate to cardiovascular, respiratory and digestive systems. It should also be mentioned that 4.76 per cent of the population suffer from mental and behavioural problems, and four per cent have oncological diseases. Ukraine has a large number of qualified physicians (of whom many are English-speaking), a number of potential and acting clinical sites for conducting clinical trials, as well as a considerable pool of potential patients. However, the country’s economic situation affects the level of financing of the state healthcare system. This is the reason why almost all medical expenses are paid for by the individual.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Lidia Gomenyuk graduated from the paediatric department of the Ukrainian National Medical University in 1997. She then undertook an internship in paediatrics between 1997 and 1998. From 1998 to 2000, she worked in the paediatric cardiology department of Kyiv Municipal Paediatric Hospital number 2. Between 2000 and 2002, she worked in the diagnostic department of the National Centre for Radiation Medicine. Since 2000, she has initiated and headed the Clinical Trial Unit at Dila Medical Laboratory.

Marina Gornostai graduated from the National Medical University of Ukraine in 1998, and obtained a postgraduate qualification in economics in 2009. She worked as a paediatrician from 1998 to 2004. From 2004 to 2006 she worked at the sales department of Nycomed - Ukraine, and from 2006 to 2007 at JSC Pharmak, where she was responsible for the organisation of clinical trials. Marina has been working at Dila Medical Laboratory since 2007 as a marketologist.

spacer
Lidia Gomenyuk
spacer
spacer
spacer
Marina Gornostai
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

[Noáin, April 22, 2020] 3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement